Follicular Lymphoma: efficacy of Rituximab maintenance after ten years of follow-up

 These results from the PRIMA study conducted by LYSA were presented at the international congress of the American Society of Hematology (ASH) in Atlanta in the USA on 10 December.

“When a patient in two who received a first-line immunochemotherapy and rituximab maintenance has not relapsed after ten years, can we still consider that follicular lymphoma is incurable?”, asks Pr. Gilles Salles, president of LYSA, LYSARC and CALYM.

Discover all the press release (in French) (.pdf)!